
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc demonstrates a positive outlook driven by the anticipated growth of its POSLUMA product, which is projected to increase its U.S. revenue and unit share significantly by the first quarter of 2025. Additionally, the new Pylarify formulary, expected to enhance batch size by approximately 50%, alongside three years of therapy protocol eligibility, is likely to revitalize Pylarify's growth trajectory beginning in the fourth quarter of 2026. Overall, the combination of product advancements and strategic developments positions Lantheus for promising financial performance in the coming years.
Bears say
Lantheus Holdings Inc has experienced a decline in its revenue from Pylarify, generating $260 million, which reflects an 8% year-over-year decrease and falls approximately $14 million short of consensus expectations. The company's two-year growth profile has now positioned it below its profitable SMID MedTech peers, compounded by a reduction in Pylarify growth forecasts for 2025-2026. Additionally, weak unit growth of only 2% year-over-year, combined with a significant 10% price headwind during the quarter, underscores challenges in maintaining revenue momentum.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares